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Abstract. A total of 136 patients, 67 HIV, 69 diabetes mellitus (DM) with or without (±) end-stage renal disease 
(ESRD), were registered for tuberculosis treatment at the National Tuberculosis Center (NTBC) from May 
to December, 2003. Ages ranged from 21-78 years (median 57.7 years) in TB/DM patients, and 21-62 (mean 
37.6 ± 8.3 years) in TB/HIV patients. TB was significantly found in younger and single HIV patients, but in 
older and married DM patients (p<0.05). Male patients in both groups were strongly associated with TB, while 
females more commonly had TB with DM (p<0.05). The majority of these patients were Malays, unemployed, 
and resided in Kuala Lumpur territory; however, no statistically significant difference was found between the 
2 groups. Smoking, IVDUs and hepatitis C virus (HCV) infection were more significantly found in TB/HIV 
patients and further analysis showed that pulmonary TB was strongly associated with HCV infection in these 
patients (p<0.05). Pulmonary TB (62; 89.9%) was the most common type found in both groups and was a 
markedly more common disease location in TB/DM patients, while extrapulmonary TB (21; 31.3%) and miliary 
TB (14; 21%) were significantly higher in TB/HIV patients. Cough with or without sputum, fever and loss of 
appetite and/or weight were common clinical presentations in both groups. Nevertheless, fever (54; 80.6%) and 
lymphadenopathy (17; 25.4%) were significantly related to TB/HIV patients (p<0.05). Interestingly, the presence 
of BCG vaccination and positive tuberculin skin test were stronger in TB/HIV (27; 40.3%) and TB/DM (20; 
29%) patients, respectively (p<0.05). Overall, regular 6-, 9- and 12-months’ anti-tubercular therapy (ATT) were 
routine practice, and EHRZ+B6 was the most common regimen used. The highest percentage of patients with 
treatment success were in both groups with 6 months’ ATT; however, a significantly higher percentage was found 
in TB/DM (24; 34.8%) than TB/HIV (13; 19.4%) (p<0.05). A success rate of 15 (21.7%) was noted for TB/DM 
patients with 9 months’ ATT, which was similar to both groups with the 12-month regimen. A higher percentage 
failure rate (lost to follow-up) was seen in TB/HIV (19; 28.4%) patients. Nine patients were reported to have 
anti-tubercular-drug side-effects, such as drug-induced hepatitis, blurred vision, and skin rash. No cases of drug 
resistance or death were notified among these patients.
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INTRODUCTION
 Tuberculosis (TB) is one of the most devastating 
diseases, primarily due to several decades of neglect, 
and presents a global health threat of escalating 
proportions; in addition, TB is the second leading 
infectious cause of mortality today after HIV/AIDS 
(Nayyar and Jain, 2005). TB continues to be a major 
public health problem, not only in developed countries, 
but also in almost all developing countries (Siriram and 
Arvind, 1992; Al Shohaib, 2000). Sub-Saharan Africa 
carries the overwhelming share of the global burden 
of HIV/AIDS and of HIV-associated TB (Maher et al, 
2005). In a given population, one expects to see TB, 
DM and HIV in varying combinations. TB may lack 
the characteristic clinical and histological picture due 
to associated depressed cell-mediated immunity in both 
DM and HIV, and TB may have an unusual clinical 
presentation and cytology picture (Sridhar et al, 2002). 
Moreover, HIV not only makes the diagnosis of TB 
more difficult; it also contributes to an increase in TB 
incidence (Narain et al, 1992; Raviglione et al, 1992). 
This study was therefore conducted to determine the 
comparative distributions of tuberculosis in terms of 
epidemiological, clinical manifestations, investigation 
and treatment outcomes, between diabetic and/or end-
stage renal failure (ESRD) and HIV-infected patients. 
These findings contribute significant evidence for better 
understanding and proper management, including 
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registered for tuberculosis treatment at the National 
Tuberculosis Center (NTBC) from May to December, 
2003. This center is a tertiary-level national reference 
center for respiratory diseases in Kuala Lumpur, 
Malaysia. Any person with a respiratory problem 
can attend this center without a physician’s referral. 
The majority of notified TB cases in Kuala Lumpur 
territory each year are treated there. Data from each 
patient’s medical record were reviewed retrospectively. 
Socio-demographic profiles, clinical presentations, 
investigation results, treatment, patient compliance 
with therapy, and outcomes of therapy response, were 
included in a standardized data collection sheet. AIDS-
defining illnesses were also based on the 1993 CDC 
classification.
 The case definitions were obtained from the World 
Health Organization (WHO, 2002).
 A case of tuberculosis was defined as a patient 
in whom tuberculosis has been bacteriologically 
confirmed, or has been diagnosed by a clinician. 
 A pulmonary tuberculosis, sputum-smear-positive 
(PTB+) case was defined as two or more initial sputum 
smear examinations positive for acid-fast bacilli (AFB) 
or one sputum smear examination positive for AFB 
plus radiological abnormalities consistent with active 
pulmonary tuberculosis as determined by a clinician, 
or one sputum smear positive for AFB plus sputum 
culture positive for M. tuberculosis.
 A pulmonary tuberculosis, sputum-smear-negative 
(PTB-) case was defined as a case of pulmonary 
tuberculosis not meeting the above definition for 
smear-positive TB. In keeping with good clinical 
and public health practices, diagnostic criteria should 
include: at least three sputum specimens negative for 
AFB, and radiographic abnormalities consistent with 
active pulmonary tuberculosis, and no response to a 
course of broad-spectrum antibiotics, and decision by a 
clinician to treat with a full course of anti-tuberculosis 
chemotherapy.
 An extrapulmonary tuberculosis case was defined 
as tuberculosis of organs other than the lungs, such as 
pleura, lymph nodes, abdomen, genitourinary tract, 
skin, joints, bones, and meninges. Disease should be 
based on one culture-positive specimen, or histological 
or strong clinical evidence consistent with active 
extrapulmonary tuberculosis, followed by a decision by 
a clinician to treat with a full course of anti-tuberculosis 
chemotherapy.
Categories of patients for registration
 New: a patient who has never had treatment for 
TB or has taken anti-tuberculosis drugs for less than 
one month.
 Relapse: a patient previously treated for TB who 
has been declared cured or has completed treatment, 
and is diagnosed with bacteriologically positive (smear 
or culture) tuberculosis.
 Failure: a patient who, while on treatment, is 
sputum-smear-positive at 5 months or later during the 
course of treatment.
 Return after default: a patient who returns for 
treatment with positive bacteriology, following an 
interruption of treatment for two or more months.
 Transfer in: A patient who has been transferred 
from another tuberculosis register to continue 
treatment.
Categories of treatment outcomes
 Cure: a patient who is sputum-smear-negative in 
the last month of treatment and on at least one previous 
occasion.
 Treatment completed: a patient who has 
completed treatment but who does not meet the criteria 
to be classified as cured or failure.
 Treatment failure: a patient who is sputum-smear-
positive at five months or later during treatment.
 Died: a patient who dies for any reason during the 
course of treatment.
 Defaulter: a patient whose treatment was 
interrupted for 2 or more consecutive months.
 Transfer out: a patient who has been transferred 
to another unit and for whom the treatment outcome 
is not known.
 Treatment success: a patient who is cured and 
who has completed treatment.
Statistical analysis
 The data were analyzed using the statistical 
software, SPSS version 10 (SPSS Inc, Chicago, Ill, 
USA). Data with quantitative variables were expressed 
by mean (± SD) and range, while qualitative variables 
were estimated by frequency and percentage. Statistical 
analysis was estimated using chi-square test, where 
appropriate. A p-value of <0.05 was regarded as 
statistically significant.
RESULTS
 Table 1 shows the comparative distribution of 
demographic profiles between 69 TB/DM and/or 
end-stage renal disease (ESRD) and 67 TB/HIV 
patients. Ages ranged from 21 to 78 (median 57.7) 
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Table 1
Demographic characteristics of 136 immunosppressed patients attended at the National Tuberculosis Center 
(NTBC).
 Variables No. of TB patients (%) p-value
  TB/DM ± ESRDa (69) TB/ HIV (67)
Range of age  21-78 years 21-62 years 
 Median = 57.7 Mean ± SD = 37.6 ± 8.32 
Age group (year)     0.000
15-24 2 (2.9) 5 (7.5) 
25-34 0  15 (22.4) 
35-44 3 (4.3) 36 (53.7) 
45-54 18 (26) 10 (15) 
≥ 55 46 (68.7) 1 (1.5) 
Sex     0.000
Male 42 (60.1) 59 (88) 
Female 27 (39.1) 8 (12) 
Race     0.534
Malay  36 (52.1) 39 (58.2) 
Chinese 18 (26) 13 (19.4) 
Indian  11 (16) 8 (12) 
Foreigner 4 (5.8) 7 (10.5) 
Marital status     0.000
Single 6 (8.7) 42 (62.7) 
Married 63 (91.3) 25 (37.3) 
Career     0.229
Unemployed 56 (81.2) 46 (68.7) 
Laborer 7 (10.2) 10 (15) 
Nonlaborer 6 (8.7) 11 (16.4) 
Address     0.973
Kuala Lumpur 41 (59.4) 40 (59.7) 
Outsider 28 (40.6) 27 (40.3) 
Mode of HIV transmission     0.000
Heterosexual 0  8 (12) 
Intravenous drug users (IVDU) 0  42 (62.7) 
Heterosexual-IVDU 0  2 (3) 
No record 69 (100) 15 (22.4) 
Other risk factors     0.000
Smoking 19 (27.5) 28 (41.8) 
Alcohol consumption 0  8 (12) 
Smoking and drinking 3 (4.3) 7 (10.5) 
No record 47 (68.1) 24 (35.8) 
HBV infection     0.001
Negative 16 (23.2) 31 (46.3) 
Positive 1 (1.5) 6 (9) 
No record 52 (75.4) 30 (44.8)
HCV infection     0.000
Negative 13 (18.8) 7 (10.5) 
Positive 2 (2.9) 31 (46.3) 
No record 54 (78.3) 29 (43.3) 
(Continued)
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years in TB/DM patients, and 21-62 (mean 37.6 ± 8.3) 
years in TB/HIV patients. TB was more significant in 
the younger and single HIV cases, but in older and 
married DM patients. Male patients in both groups 
were strongly associated with TB; while females 
more commonly had TB with DM. The majority of 
these patients were Malay, unemployed, and resided 
in Kuala Lumpur territory; however, no statistically 
significant difference was found between the 2 groups. 
Smoking, IVDU, hepatitis B virus (HBV), hepatitis C 
virus (HCV) infections, and BCG vaccination, were 
more significantly found in TB/HIV patients. Further 
analysis showed that pulmonary TB was strongly 
associated with HCV infection in HIV patients. 
Newly diagnosed TB cases were found in TB/DM 
(67; 97%) and TB/HIV (61; 91%) patients. From our 
data, 8 patients had a history of previous TB–4 (3 
HIV and 1 DM) cases of relapse, 2 cases of HIV with 
default to treatment, and the remaining 2 (1 HIV and 
1 DM) cases were unrecorded. The lung was the most 
common location for DM (60; 87%) and HIV (39; 
58.2%) patients. Each case of TB lung and kidney 
or pleura was diagnosed in DM patients, whilst 6 
cases of TB lung and lymph node and 1 case of TB 
lung, lymph node and pleura were diagnosed in HIV-
positive patients. Miliary was the most frequent site 
of extrapulmonary TB (ETB); which was found in 8 
HIV patients and 6 cases of miliary and disseminated 
(lymph node, pleura, hip and mandibular) were also 
reported in these patients. The lymph node was the 
most common ETB found in DM patients, while each 
case of miliary, spine, skin and eye were also diagnosed 
in these patients. Overall, PTB was more significantly 
diagnosed in TB/DM patients, and ETB was more 
frequently notified in TB/HIV patients.
 This study showed that cough with or without 
sputum, fever and loss of appetite and/or weight were 
more common clinical presentations in both groups. 
Nevertheless, fever and lymphadenopathy were more 
significantly found in TB/HIV patients. Surprisingly, 
positive tuberculin skin test was strongly related to 
TB/DM patients. Sputum smear (32; 46.4% in TB/DM 
vs 27; 40.3% in TB/HIV) and culture (37; 53.6% in TB/
DM vs 29; 43.3% in TB/HIV) were used to verify the 
presence of Mycobacterium TB; however, there was no 
statistical significance. The chest radiograph was a very 
useful tool in this study; where the majority of HIV (29; 
43.3%) and DM ± ESRD (37; 53.6%) patients showed 
typical upper lobe opacity among TB-positive patients. 
Overall, the regular 6-, 9- and 12-months’ anti-tubercular 
therapy (ATT) were registered; while EHRZ+B6 was 
the most common regimen used in these patients. The 
highest percentage of patients with treatment success 
was found in both groups of 6-month anti-tubercular 
regimen; however, a significantly higher percentage was 
 Variables No. of TB patients (%) p-value
  TB/DM ± ESRDa (69) TB/ HIV (67)
BCG vaccination     0.001
No 19 (27.5) 3 (4.5) 
Yes 19 (27.5) 27 (40.3) 
No record 31 (45) 37 (55.2) 
History of contact previous TB      0.954
No 62 (89.9) 60 (89.5) 
Yes 7 (10.1) 7 (10.5) 
Case category   
New case 67 (97.1) 61 (91) 0.354
History of previous tuberculosis   
 With completed treatment (relapse) 1 (1.5) 3 (4.5)
 With defaulted treatment 0  2 (3.0)
 No treatment record 1 (1.5) 1 (1.5) 
Type of tuberculosis     0.001
Pulmonary TB 60 (87) 39 (58.2) 
Pulmonary TB-extrapulmonary TB 2 (2.9) 6 (9) 
Extrapulmonary TB 7 (10.1) 21 (31.3)
aTB/DM ± ESRD means TB/DM with or without ESRD.
Table 1
(Continued)
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found in TB/DM (24; 34.8%) than TB/HIV (13; 19.4%) 
patients. A success rate of 15 (21.7%) was also found in 
TB/DM patients with 9 months’ ATT; which was similar 
to the 2 12-month-regimen groups. A higher percentage 
failure rate (lost to follow-up) was seen in TB/HIV (19; 
28.4%). Nine patients were reported to have side-effects 
to anti-tubercular drugs, such as drug-induced hepatitis, 
blurred vision, and skin rash. No case of drug resistance 
or death was notified during the study, as demonstrated 
in Table 2.
Table 2
Clinical manifestations and treatment outcomes of these patients.
  Variables No. of patients p-value
  TB/DM ± ESRDa (69) TB/ HIV (67)
 
Clinical manifestations   
Fever 35 (50.7) 54 (80.6) 0.000
Cough 57 (82.6) 56 (83.6) 0.880
Sputum 42 (60.9) 37 (55.2) 0.505
Hemoptysis 18 (26.1) 10 (15) 0.108
Loss of appetite and/or weight 48 (69.6) 55 (82) 0.088
Lymphadenopathy (cervical) 0  17 (25.4) 0.000
Dyspnea 12 (17.4) 15 (22.4) 0.465
Others eg, chest, back, or abdomen pain 9 (13)   6 (9) 0.639
Investigation   
Tuberculin skin test     0.002
Negative 15 (21.7) 16 (24) 
Positive 20 (29) 4 (6) 
No record 34 (49.3) 47 (70.2) 
Sputum smear     0.676
Negative 36 (52.2) 38 (56.7) 
Positive 32 (46.4) 27 (40.3) 
No record 1 (1.5)   2 (3) 
Sputum culture     0.340
Negative 27 (39) 29 (43.3) 
Positive 37 (53.6) 29 (43.3) 
No record   5 (7.3)   9 (13.4) 
Chest radiograph findings     0.000
Normal   6 (8.7)   4 (6) 
Positive for PTB 60 (87) 38 (56.7) 
Positive for PTB and disseminated   2 (2.9)   7 (10.5) 
Positive for ETB   2 (2.9) 17 (25.4) 
Tissue biopsy     0.415
Positive   7 (10.2)   5 (7.5) 
No record   3 (4.4)   0 
Other results    
CT scan, MRI, ultra-sound, echocardiogram,   5 (7.3)   3 (4.5) 0.505
PCR, pleural fluid and ophthalmoscope   
Treatment outcomes   
Loss to follow-up 15 (21.7) 19 (28.4) 0.373
Transfer out   2 (2.9) 15 (22.4) 0.001
Ongoing < 6 months   8 (11.6)   5 (7.5) -
Success ≥ 6 months 24 (34.8) 13 (19.4) 0.044
Success ≥ 9 months 15 (21.7)   8 (12) 0.204
Success ≥ 12 months   5 (7.3)   6 (9) 0.715
aTB/DM ± ESRD means TB/DM with or without ESRD.
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 In addition, it is important to mention TB in 8 
of the ESRD patients whom we were able to include 
during this study; 2 were diagnosed with DM as an 
underlying cause, and the other 6 patients showed no 
record. The majority of these patients were in the age 
group ≥45 years (5 patients) and female (6 patients). 
Only 1 patient showed positive for tuberculin skin test 
and 5 patients had BCG vaccination. Overall, patients 
had typical clinical pulmonary manifestation, eg fever 
(2 cases), cough (5), sputum (2), hemoptysis (1), and 
loss of weight and/or appetite (3). Chest radiograph was 
the main investigation to confirm all 6 patients with 
pulmonary TB. Five patients presented with pulmonary 
tuberculosis, 1 case with pulmonary and disseminated 
TB (lung and kidney), and 2 cases with ETB (1 each for 
miliary and skin). The most common anti-tubercular 
drug regimen used was HRZ+B6. The outcome showed 
that 3 patients had treatment success in durations of 6, 9, 
and 12 months, while 3 patients were treatment ongoing, 
and the remaining 2 were lost to follow-up. No case of 
death or drug resistance was notified in these patients 
during this study (data not shown).
DISCUSSION
 The proportion of tuberculosis developing 
particularly from compromized hosts in high-risk 
groups is especially high (Anonymous, 2003). From 
our data, the trend of TB was significantly higher 
among males (Stead and To, 1987; Holmes et al, 
1998; Pérez-Guzmán et al, 2003) in both groups, 
younger and single HIV (25-44 years) but in older 
and married DM (≥ 45 years) patients. This finding 
has been reported elsewhere and coincides with the 
existing epidemiological viewpoint. Smoking was 
shown in a high percentage of both groups, but more 
significantly higher in TB/HIV patients. One study 
interestingly reported that persons with exposure 
to active and passive smoking had a higher risk of 
pulmonary TB; therefore, an effective anti-smoking 
campaign is expected to have positive repercussions 
on TB incidence (Ariyothai et al, 2004). In addition, 
intravenous drug use and HCV infection were also 
found in markedly higher percentages among TB/HIV 
patients. Our finding conforms the strong associations 
of these important risk factors. Further studies are 
needed to assess the impact of the high prevalence of 
HCV co-infection on treatment outcomes, including 
tolerability and risk of anti-tuberculosis drug induced 
hepatotoxicity (Richards et al, 2006). The presence 
of BCG vaccination was even more commonly found 
in TB/HIV patients, and its role in TB prevention has 
been widely debated and questioned for its efficacy 
(Anonymous, 1990; Hashimoto, 1997; Lugosi, 1998; 
Mori, 2001). Nevertheless, we still support and 
recommend this primary TB preventive measure, 
since no alternative vaccine has currently been proven 
more effective in combating TB infection. We found 
few relapse cases; however, it plays no significant role 
in contributing to the occurrence of TB. One study 
showed that many other factors have contributed to 
relapse, such as delay in negative conversion of sputum 
culture, noncompliance, diabetes mellitus, and male 
cases aged in their 50s (Sasaki et al, 2003).
 In the clinical scenario, pulmonary tuberculosis 
(PTB) is the most common form of TB, as reported in 
the literature and in our present study. PTB was higher 
in TB/DM patients; therefore, good control of DM is 
important to prevent the exacerbation of TB in these 
patients (Yoshitomi et al, 1998). Miliary TB was the 
most common ETB found in these patients, and had 
a higher rate in TB/HIV patients. The CXR finding is 
the most useful tool in diagnosing this form of TB, 
as evidenced in all cases of this study, to ensure early 
diagnosis and treatment to reduce the mortality rate 
in these patients. The majority of TB/DM patients 
showed opacity in the upper or middle zones of the 
lung. This finding is contrary to one recent study 
where DM patients were more likely to present with 
atypical radiological images and present with lower 
lung field lesions or cavities. The possibility of TB 
should always be considered for prompt diagnosis 
and management (Shaikh et al, 2003). Patients lost to 
follow-up were found in both groups, but the rate was 
higher among TB/HIV patients. The main reason for 
ineffective chemotherapy was noncompliance, while 
various factors have been verified, particularly in DM 
patients, such as severity of the DM course and its 
complications, the spread of TB, and the resistance 
of MTB to preparations (Voloshyn et al, 1999). Even 
though there was no drug resistance in these patients, 
one study has shown that MDR-TB was marginally 
higher in HIV-positive patients than in the non-HIV-
infected population (Swaminathan et al, 2005). At 
this moment, we support INH prophylaxis; which 
has proven effective for HIV-infected patients in 
many settings. However, chemoprophylaxis must be 
administered to the patient for a long period, for at least 
6 months, which may challenge patient compliance; 
in addition, a 2-month course of rifampicin and 
pyrazinamide daily can be used instead of INH alone 
(Narain and Lo, 2004).
 TB in ESRD patients has consistently gained 
attention as part and parcel of DM and other chronic-
disease patients. There is an increased risk (6-9 to 
52.5-fold) of TB in these patients compared with the 
general population (Hussein et al, 2003). Surprisingly, 
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no such study has been reported in Southeast Asia, 
including Malaysia. From our analysis, all patients 
presented with typical respiratory signs and symptoms 
which can assist in diagnosis. One study suggested that 
such patients in an endemic area, who present with 
FUO, should be carefully evaluated for TB, and TB 
test therapy should immediately be performed (Erkoc 
et al, 2004). Moreover, FUO, reverse serum albumin/
globulin ratio, and unexplained hyperglycemia in 
these patients suggested the possibility of TB (Fang 
et al, 2004). Only 3 patients had extrapulmonary 
TB in our finding; however, one study showed that 
extrapulmonary TB is common in ESRD patients, 
and lymph node involvement was the most common 
extrapulmonary presentation (Lund et al, 2000). 
Regular tuberculin skin test (TST) evaluation, in 
combination with a chest X-ray, is a useful tool to 
detect M. tuberculosis infection in these patients 
(Wauter et al, 2004). Overall, TB prophylaxis is 
recommended in patients with a positive TST and 
radiographs suggesting old TB (Hussein et al, 2003), 
and its side effects were not a major problem in this 
group of patients (Agarwal et al, 2004). Therefore, 
identification of such factors related to TB in ESRD 
patients would be highly interesting and deserving of 
further larger-scale study, to enhance proper diagnosis 
and management for these patients.
 In conclusion, this study showed some insights into 
TB, which remains a major challenge and continues to 
be an enormous public health problem, particularly for 
people in developing countries. The implementation 
of TB intervention and network collaborations, 
particularly in HIV-infected patients, needs to be 
highlighted, to help and generate common feasibilities 
to improve life expectancy among these patients and 
curb the future incidence of TB.
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